| Grace Louise Greer, DO | |
|
1 Healthy Way, Oceanside, NY 11572-1551 | |
| (516) 632-2000 | |
| Not Available |
| Full Name | Grace Louise Greer |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 1 Healthy Way, Oceanside, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730591082 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 288802 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Hospital Medical Center | West islip, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Suffolk Medical Pc | 0244396349 | 138 |
News Archive
A CDC food safety alert regarding a multistate outbreak of Salmonella Enteritidis infections has been posted: https://www.cdc.gov/salmonella/enteritidis-06-21/index.html
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.
People who have recovered from COVID-19, especially those with pre-existing cardiovascular conditions, may be at risk of developing blood clots due to a lingering and overactive immune response, according to a study led by Nanyang Technological University, Singapore (NTU) scientists.
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
Researchers at Case Western Reserve University School of Medicine have shown a high fat diet may lead to specific changes in gut bacteria that could fight harmful inflammation-a major discovery for patients suffering from Crohn's disease.
› Verified 3 days ago
| Entity Name | South Nassau Communities Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922079094 PECOS PAC ID: 5092607846 Enrollment ID: O20040326000373 |
News Archive
A CDC food safety alert regarding a multistate outbreak of Salmonella Enteritidis infections has been posted: https://www.cdc.gov/salmonella/enteritidis-06-21/index.html
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.
People who have recovered from COVID-19, especially those with pre-existing cardiovascular conditions, may be at risk of developing blood clots due to a lingering and overactive immune response, according to a study led by Nanyang Technological University, Singapore (NTU) scientists.
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
Researchers at Case Western Reserve University School of Medicine have shown a high fat diet may lead to specific changes in gut bacteria that could fight harmful inflammation-a major discovery for patients suffering from Crohn's disease.
› Verified 3 days ago
| Entity Name | Southwest Suffolk Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104096049 PECOS PAC ID: 0244396349 Enrollment ID: O20090225000297 |
News Archive
A CDC food safety alert regarding a multistate outbreak of Salmonella Enteritidis infections has been posted: https://www.cdc.gov/salmonella/enteritidis-06-21/index.html
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.
People who have recovered from COVID-19, especially those with pre-existing cardiovascular conditions, may be at risk of developing blood clots due to a lingering and overactive immune response, according to a study led by Nanyang Technological University, Singapore (NTU) scientists.
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
Researchers at Case Western Reserve University School of Medicine have shown a high fat diet may lead to specific changes in gut bacteria that could fight harmful inflammation-a major discovery for patients suffering from Crohn's disease.
› Verified 3 days ago
| Entity Name | Mount Sinai School Of Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508127531 PECOS PAC ID: 6406096544 Enrollment ID: O20130712000368 |
News Archive
A CDC food safety alert regarding a multistate outbreak of Salmonella Enteritidis infections has been posted: https://www.cdc.gov/salmonella/enteritidis-06-21/index.html
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.
People who have recovered from COVID-19, especially those with pre-existing cardiovascular conditions, may be at risk of developing blood clots due to a lingering and overactive immune response, according to a study led by Nanyang Technological University, Singapore (NTU) scientists.
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
Researchers at Case Western Reserve University School of Medicine have shown a high fat diet may lead to specific changes in gut bacteria that could fight harmful inflammation-a major discovery for patients suffering from Crohn's disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Grace Louise Greer, DO 1 Healthy Way, Oceanside, NY 11572-1551 Ph: () - | Grace Louise Greer, DO 1 Healthy Way, Oceanside, NY 11572-1551 Ph: (516) 632-2000 |
News Archive
A CDC food safety alert regarding a multistate outbreak of Salmonella Enteritidis infections has been posted: https://www.cdc.gov/salmonella/enteritidis-06-21/index.html
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.
People who have recovered from COVID-19, especially those with pre-existing cardiovascular conditions, may be at risk of developing blood clots due to a lingering and overactive immune response, according to a study led by Nanyang Technological University, Singapore (NTU) scientists.
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
Researchers at Case Western Reserve University School of Medicine have shown a high fat diet may lead to specific changes in gut bacteria that could fight harmful inflammation-a major discovery for patients suffering from Crohn's disease.
› Verified 3 days ago
Kenya Crafton, FNP-BC Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Healthy Way, Oceanside, NY 11572 Phone: 516-632-3000 | |
Mary Kristine Ellis, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 196 Merrick Rd, Oceanside, NY 11572 Phone: 516-255-8400 | |
Dr. Zeeshan Alam Khan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 196 Merrick Rd, Oceanside, NY 11572 Phone: 516-255-8400 | |
Dr. Lillian Carolina, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1 Healthy Way, Oceanside, NY 11572 Phone: 516-255-8400 | |
Jamil Uddin Ahmed, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Healthy Way, Oceanside, NY 11572 Phone: 516-632-3666 | |
Dr. Shara Rebecca Feltheimer, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Healthy Way, Oceanside, NY 11572 Phone: 516-632-3000 | |
Malcolm Forbes, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Healthy Way, Oceanside, NY 11572 Phone: 516-255-8414 |